IS8280A - 2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2 - Google Patents

2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2

Info

Publication number
IS8280A
IS8280A IS8280A IS8280A IS8280A IS 8280 A IS8280 A IS 8280A IS 8280 A IS8280 A IS 8280A IS 8280 A IS8280 A IS 8280A IS 8280 A IS8280 A IS 8280A
Authority
IS
Iceland
Prior art keywords
benzmide
ylsulfonylamino
cck2
quinoxaline
regulate
Prior art date
Application number
IS8280A
Other languages
English (en)
Inventor
D. Allison Brett
D. Hack Michael
K. Phuong Victor
H. Rabinowitz Michael
D. Rosen Mark
Original Assignee
Janssen Pharmaceutica, N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica, N.V. filed Critical Janssen Pharmaceutica, N.V.
Publication of IS8280A publication Critical patent/IS8280A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Structural Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8280A 2003-08-08 2006-01-31 2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2 IS8280A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49407403P 2003-08-08 2003-08-08
PCT/US2004/025153 WO2005016896A1 (en) 2003-08-08 2004-08-04 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators

Publications (1)

Publication Number Publication Date
IS8280A true IS8280A (is) 2006-01-31

Family

ID=34193199

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8280A IS8280A (is) 2003-08-08 2006-01-31 2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2

Country Status (33)

Country Link
US (3) US7304051B2 (is)
EP (2) EP1651622B1 (is)
JP (2) JP2007501842A (is)
KR (1) KR20060060007A (is)
CN (2) CN1863782A (is)
AR (1) AR045930A1 (is)
AT (2) ATE403650T1 (is)
AU (2) AU2004265312B2 (is)
BR (1) BRPI0413449A (is)
CA (2) CA2534885C (is)
CR (1) CR8229A (is)
CY (1) CY1106486T1 (is)
DE (2) DE602004015614D1 (is)
DK (2) DK1651622T3 (is)
EA (1) EA200600203A1 (is)
EC (1) ECSP066355A (is)
ES (2) ES2310294T3 (is)
HR (1) HRP20080559T3 (is)
IL (1) IL173591A0 (is)
IS (1) IS8280A (is)
LT (1) LT5410B (is)
LV (1) LV13453B (is)
MX (2) MXPA06001482A (is)
NO (1) NO20061122L (is)
NZ (1) NZ545030A (is)
PL (2) PL1651621T3 (is)
PT (2) PT1651622E (is)
SG (1) SG131114A1 (is)
SI (2) SI1651621T1 (is)
TW (1) TW200521120A (is)
UA (1) UA84025C2 (is)
WO (2) WO2005016896A1 (is)
ZA (1) ZA200601946B (is)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1651621T1 (sl) * 2003-08-08 2008-12-31 Janssen Pharmaceutica Nv 2-(kinoksalin-5-ilsulfonilamino)-benzamidne spojine kot modulatorji CCK2
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US7947833B2 (en) * 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
MX2007003623A (es) 2004-09-24 2007-09-11 Johnson & Johnson Compuestos sulfonamida.
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US8592565B2 (en) * 2007-01-12 2013-11-26 The Board Of Trustees Of The Leland Stanford Junior University Preparation of azide-modified carbon surfaces for coupling to various species
JP5497429B2 (ja) * 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
WO2008124518A1 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
EP2131243B1 (en) * 2008-06-02 2015-07-01 ASML Netherlands B.V. Lithographic apparatus and method for calibrating a stage position
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
WO2010118208A1 (en) * 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド 肥満治療に用いられるスルホン化合物
WO2012004604A1 (en) 2010-07-09 2012-01-12 Convergence Pharmaceuticals Limited Tetrazole compounds as calcium channel blockers
AU2011281037B2 (en) 2010-07-22 2014-11-27 Zafgen, Inc. Tricyclic compounds and methods of making and using same
CN103402989B (zh) 2011-01-26 2016-04-06 扎夫根股份有限公司 四唑化合物及其制备和使用方法
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
MX345535B (es) 2011-05-06 2017-02-03 Zafgen Inc Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
CA2835195A1 (en) 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン，インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
ES2683046T3 (es) * 2012-03-01 2018-09-24 Allergan, Inc. Derivados de benzofuran-2-sulfonamida como moduladores del receptor de quimiocinas
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
WO2014071363A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
CN103524386B (zh) * 2013-10-24 2016-05-18 江苏鼎龙科技有限公司 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
RU2693484C1 (ru) 2013-11-22 2019-07-03 СиЭль БАЙОСАЕНСИЗ ЭлЭлСи Антагонисты гастрина для лечения и профилактики остеопороза
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN106565509A (zh) * 2016-11-03 2017-04-19 江苏鼎龙科技有限公司 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法
KR101894091B1 (ko) * 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN108218806B (zh) * 2018-04-02 2019-03-01 上海馨远医药科技有限公司 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法
CN111285806B (zh) * 2018-12-06 2022-04-15 中国医学科学院药物研究所 吡唑类化合物及其制备方法、用途和药物组合物
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200420D0 (en) 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
ATE197146T1 (de) 1993-08-10 2000-11-15 Black James Foundation Gastrin-und cck-rezeptorligande
ATE248823T1 (de) 1996-12-10 2003-09-15 Zeria Pharm Co Ltd 1,5-benzodiazepinderivate
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
ITTO20020674A1 (it) 2002-07-26 2004-01-26 Rotta Research Lab Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
US6943170B2 (en) * 2002-11-14 2005-09-13 Bristol-Myers Squibb Company N-cycloalkylglycines as HIV protease inhibitors
SI1651621T1 (sl) 2003-08-08 2008-12-31 Janssen Pharmaceutica Nv 2-(kinoksalin-5-ilsulfonilamino)-benzamidne spojine kot modulatorji CCK2
MX2007003623A (es) * 2004-09-24 2007-09-11 Johnson & Johnson Compuestos sulfonamida.

Also Published As

Publication number Publication date
US20050038032A1 (en) 2005-02-17
KR20060060007A (ko) 2006-06-02
JP4818110B2 (ja) 2011-11-16
JP2007501842A (ja) 2007-02-01
US20050043310A1 (en) 2005-02-24
AU2004265311A1 (en) 2005-02-24
CN1863781A (zh) 2006-11-15
CN1863782A (zh) 2006-11-15
BRPI0413449A (pt) 2006-10-17
PT1651622E (pt) 2007-04-30
EP1651621B1 (en) 2008-08-06
US7304051B2 (en) 2007-12-04
PL1651622T3 (pl) 2007-07-31
DE602004004663T2 (de) 2007-11-22
DK1651621T3 (da) 2008-11-10
US7288651B2 (en) 2007-10-30
ATE403650T1 (de) 2008-08-15
CA2534887A1 (en) 2005-02-24
ECSP066355A (es) 2006-08-30
EP1651622B1 (en) 2007-02-07
CR8229A (es) 2008-09-10
SI1651621T1 (sl) 2008-12-31
CY1106486T1 (el) 2012-01-25
US20080076918A1 (en) 2008-03-27
AU2004265312B2 (en) 2010-05-20
DE602004015614D1 (de) 2008-09-18
LT5410B (lt) 2007-03-26
MXPA06001482A (es) 2006-09-04
CA2534885A1 (en) 2005-02-24
ZA200601946B (en) 2007-05-30
EP1651621A1 (en) 2006-05-03
JP2007501841A (ja) 2007-02-01
HRP20080559T3 (en) 2009-01-31
NZ545030A (en) 2009-08-28
DK1651622T3 (da) 2007-05-07
ES2281834T3 (es) 2007-10-01
NO20061122L (no) 2006-05-04
EA200600203A1 (ru) 2006-08-25
LV13453B (en) 2007-02-20
WO2005016896A1 (en) 2005-02-24
WO2005016897A1 (en) 2005-02-24
DE602004004663D1 (de) 2007-03-22
US7563895B2 (en) 2009-07-21
MXPA06001550A (es) 2006-09-04
ATE353322T1 (de) 2007-02-15
PL1651621T3 (pl) 2009-01-30
EP1651622A1 (en) 2006-05-03
ES2310294T3 (es) 2009-01-01
AU2004265312A1 (en) 2005-02-24
UA84025C2 (en) 2008-09-10
SI1651622T1 (sl) 2007-06-30
IL173591A0 (en) 2006-07-05
AR045930A1 (es) 2005-11-16
CA2534885C (en) 2013-06-04
SG131114A1 (en) 2007-04-26
PT1651621E (pt) 2008-09-30
TW200521120A (en) 2005-07-01
LT2006017A (en) 2006-11-27

Similar Documents

Publication Publication Date Title
IS8280A (is) 2-(qinoxalín-5-ýlsúlfónýlamínó)-benzmíðefnasambönd sem stillar CCK2
IS8108A (is) Ný efnasambönd
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
IS7471A (is) Ný efnasambönd
NO20054005D0 (no) Nye arylpiperazinylforbindelser
SE0301569D0 (sv) Novel compounds
ATE368042T1 (de) Cephemverbindungen
IS8228A (is) Ný asetídínefnasambönd
IL173079A0 (en) Ppar active compounds
IS7827A (is) Ný efnasambönd
IS7381A (is) Efnasambönd
IS8089A (is) Efnasambönd
IS8292A (is) Ný efnasambönd
IS7414A (is) Oxó-azabísýklísk efnasambönd
NO20045659L (no) Forbindelser
NO20055097D0 (no) Krystallinske N-formyl-hydroksylaminforbindelser
NO20031736D0 (no) Forbindelser
SE0303452D0 (sv) New compounds
SI1648867T1 (sl) Ppar aktivne spojine
SE0203348D0 (sv) Novel compounds
SE0302369D0 (sv) New compounds
SE0303078D0 (sv) New compounds
SE0303181D0 (sv) New compounds
SE0302368D0 (sv) New compounds
SE0301305D0 (sv) New compounds